Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations.
Variceal rebleeding is a very frequent and severe complication in cirrhotic patients; therefore, its prevention should be mandatory. Lately several studies demonstrated that the rate of rebleeding was decreased by 40% and overall survival is improved by 20% with beta-blockers. However, this treatment presents some problems, such as the number of nonresponders and contraindications for its use. Recent trials found that the combination of beta-blockers with mononitrate of isosorbide to be superior to beta-blockade alone. Furthermore, endoscopic band ligation also shown to decrease the frequency of rebleeding, complications, and death compared with sclerotherapy and should be the preferred endoscopic treatment. In addition, the comparison between combined pharmacologic treatment with endoscopic treatment present similar rebleeding and mortality rates. More recently, the addition of nadolol to endoscopic band ligation increased the efficacy of endoscopy alone in the prevention of variceal rebleeding. These studies suggest that banding plus drugs could be the treatment of choice for the prophylaxis of rebleeding. When these treatments fail, the recommendation is to use transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunts. Both treatments are effective in preventing rebleeding; however, they are associated with a greater risk of encephalopathy. The comparison of portacaval shunts with TIPS demonstrated that TIPS patients presented higher rebleeding, treatment failure, and transplantation. Another randomized controlled trial comparing distal splenorenal shunt with TIPS shows that variceal rebleeding was similar in both groups without differences in encephalopathy and mortality. The only difference observed was the higher rate of reintervention observed in the TIPS group to maintain his patency.
Kravetz
David
D
San Diego Veterans Affairs Medical Center, University of California at San Diego, San Diego, CA 92161, USA. dkravetz@ucsd.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004724:Endoscopy; D004932:Esophageal and Gastric Varices / Q000150:complications* / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006489:Hemostatic Techniques; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications* / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives / Q000627:therapeutic use; D008026:Ligation; D008103:Liver Cirrhosis / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D011167:Portacaval Shunt, Surgical; D017082:Portal Pressure; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D017410:Practice Guidelines as Topic; D015911:Sclerotherapy; D055502:Secondary Prevention; D017211:Treatment Failure; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D006490:Hemostatics; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate